KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) Debt to Equity (2016 - 2023)

Pacific Biosciences Of California has reported Debt to Equity over the past 13 years, most recently at $0.13 for Q3 2023.

  • For Q3 2023, Debt to Equity changed N/A year-over-year to $0.13; the TTM value through Sep 2023 reached $0.13, changed N/A, while the annual FY2022 figure was $0.31, 6105.92% up from the prior year.
  • Debt to Equity for Q3 2023 was $0.13 at Pacific Biosciences Of California, down from $0.29 in the prior quarter.
  • Over five years, Debt to Equity peaked at $0.31 in Q4 2022 and troughed at $0.0 in Q4 2021.
  • A 4-year average of $0.21 and a median of $0.28 in 2019 define the central range for Debt to Equity.
  • Biggest five-year swings in Debt to Equity: skyrocketed 123.86% in 2019 and later soared 6105.92% in 2022.
  • Year by year, Debt to Equity stood at $0.29 in 2019, then plummeted by 98.28% to $0.0 in 2021, then soared by 6105.92% to $0.31 in 2022, then tumbled by 58.92% to $0.13 in 2023.
  • Business Quant data shows Debt to Equity for PACB at $0.13 in Q3 2023, $0.29 in Q2 2023, and $0.27 in Q1 2023.